Prognostic Value of Metabolic Response Measured by FDG-PET-CT in Patients with Breast Cancer Liver Metastasis Treated with Stereotactic Body Radiotherapy
The standardized uptake value (SUV) andsurvival rates were evaluated.RESULTSAfter a median follow-up time of 11.5 (3.2–48.9) months, there was a significant difference between preand post-SBRT SUVs (p
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:OBJECTIVETo investigate the impact of metabolic response measured by 18-fluorodeoxyglucose positron emissiontomography and computed tomography (FDG-PET-CT) in patients with breast cancer liver metastasis(BCLM) treated with stereotactic body radiotherapy (SBRT).METHODSThe medical records of 17 patients with BCLM treated with SBRT between March 2013 and October 2017were investigated retrospectively.
📊
Temel Bulgular & Veri:Patients received SBRT for their liver metastasis, and thereafter, a secondFDG-PET-CT was performed for response assessment in a median of 4.1 (2.2–8.2) months.
💡
Sonuç & Katkı:The standardized uptake value (SUV) andsurvival rates were evaluated.RESULTSAfter a median follow-up time of 11.5 (3.2–48.9) months, there was a significant difference between preand post-SBRT SUVs (p
🔬Tür:Araştırma Makalesi
📍Kapsam:2013 Verileri
⚙️Değişkenler:Alan Parametreleri
Abstract
OBJECTIVETo investigate the impact of metabolic response measured by 18-fluorodeoxyglucose positron emissiontomography and computed tomography (FDG-PET-CT) in patients with breast cancer liver metastasis(BCLM) treated with stereotactic body radiotherapy (SBRT).METHODSThe medical records of 17 patients with BCLM treated with SBRT between March 2013 and October 2017were investigated retrospectively. Patients received SBRT for their liver metastasis, and thereafter, a secondFDG-PET-CT was performed for response assessment in a median of 4.1 (2.2–8.2) months. A total of 54Gy in three fractions were delivered to liver metastatic lesions. The standardized uptake value (SUV) andsurvival rates were evaluated.RESULTSAfter a median follow-up time of 11.5 (3.2–48.9) months, there was a significant difference between preand post-SBRT SUVs (p
🔖
Bu Makaleye Atıf Yap
ÖNAL, C., TORUN, N., GÜLER, O. C., YILDIRIM, B. A. (2022). Prognostic Value of Metabolic Response Measured by FDG-PET-CT in Patients with Breast Cancer Liver Metastasis Treated with Stereotactic Body Radiotherapy. Türk Onkoloji Dergisi, Cilt: 33 - Sayı: 3, 108–114. https://ajindex.com/articles/639249
Goodman KA, Kavanagh BD. Stereotactic Body Radiotherapy for Liver Metastases. Semin Radiat Oncol 2017;27(3):240–6
Caivano D, Valeriani M, Russo I, Bonome P, DE Matteis S, Minniti G, et al. Stereotactic Body Radiation Therapy in Primary and Metastatic Liver Disease. Anticancer Res 2017;37(12):7005–10
Goodman BD, Mannina EM, Althouse SK, Maluccio MA, Cárdenes HR. Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Pract Radiat Oncol 2016;6(2):86–95
Wu SG, Li H, Tang LY, Sun JY, Zhang WW, Li FY, et al. The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis. Tumour Biol 2017;39(6):1010428317705082
Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 2008;19(12):2012–9
Adam R, Aloia T, Krissat J, Bralet MP, Paule B, Giacchetti S, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg 2006;244(6):897–907
Salama JK, Chmura SJ. The role of surgery and ablative radiotherapy in oligometastatic breast cancer. Semin Oncol 2014;41(6):790–7
Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 2006;45(7):831–7. 10.Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 2012;83(3):878–86. 11.Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009;27(10):1572–8. 12.Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 2013;86(2):336–42. 13.Higuchi I, Yasuda T, Yano M, Doki Y, Miyata H, Tatsumi M, et al. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with loca